World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
World Lung 2025 – Candel looks to a new agla-vec use
But results come from a curated dataset, with no in-trial comparator.
World Lung 2025 – Bristol seeks PRMT5 biomarkers
A common mutation comes into play for PRMT5 inhibition.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
World Lung 2025 preview – late-breakers in focus
Summit and Nuvalent have scored prized plenary spots.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
